V
Van Nguyen-Tran
Researcher at Genomics Institute of the Novartis Research Foundation
Publications - 5
Citations - 313
Van Nguyen-Tran is an academic researcher from Genomics Institute of the Novartis Research Foundation. The author has contributed to research in topics: Downregulation and upregulation & Throughput (business). The author has an hindex of 4, co-authored 5 publications receiving 268 citations.
Papers
More filters
Journal ArticleDOI
Inhibition of DYRK1A and GSK3B induces human β-cell proliferation.
Weijun Shen,Brandon Taylor,Qihui Jin,Van Nguyen-Tran,Shelly Meeusen,You-Qing Zhang,Anwesh Kamireddy,Austin De Swafford,Andrew F. Powers,John P Walker,John Lamb,Badry Bursalaya,Michael DiDonato,George Harb,Minhua Qiu,Christophe M. Filippi,Lisa Deaton,Carolina N. Turk,Wilma L. Suarez-Pinzon,Yahu Liu,Xueshi Hao,Tingting Mo,Shanshan Yan,Jing-Jing Li,Ann E. Herman,Bernhard J. Hering,Tao Wu,H. Martin Seidel,Peter McNamara,Richard Glynne,Bryan Laffitte +30 more
TL;DR: The feasibility of treating diabetes with an oral therapy to restore β-cell mass is supported, a tractable pathway for future drug discovery efforts is highlighted, and Dyrk1a is highlighted as the key molecular target.
Journal ArticleDOI
PPARδ Agonism Activates Fatty Acid Oxidation via PGC-1α but Does Not Increase Mitochondrial Gene Expression and Function
Sandra Kleiner,Sandra Kleiner,Van Nguyen-Tran,Olivia Bare,Xueming Huang,Bruce M. Spiegelman,Zhidan Wu +6 more
TL;DR: It is demonstrated that pharmacological activation of PPARδ induces FAO via PGC-1α, however, PPAR δ agonism does not induce mitochondrial gene expression and function.
Journal ArticleDOI
Discovery of 5-(3,4-Difluorophenyl)-3-(pyrazol-4-yl)-7-azaindole (GNF3809) for β-Cell Survival in Type 1 Diabetes
Zhihong Huang,Matthew S. Tremblay,Tom Y.-H. Wu,Qiang Ding,Xueshi Hao,Janine E. Baaten,Robert Hill,Bo Liu,Shelly Meeusen,Yefen Zou,Shanshan Yan,Yong Jia,Van Nguyen-Tran,Weijun Shen,Ganesh Bhat,Richard Glynne,Bryan Laffitte,Jing Li,Valentina Molteni,Yahu A. Liu +19 more
TL;DR: In vivo, orally bioavailable GNF3809 prevented elevated blood glucose level and improved oral glucose tolerance in a nonobese diabetic mouse model, and lays the foundation for development of a new class of therapeutic interventions for T1D.
Journal ArticleDOI
Characterization of a novel, brain-penetrating CB1 receptor inverse agonist: metabolic profile in diet-induced obese models and aspects of central activity
Laura H. Jacobson,S. Renee Commerford,Sarah P. Gerber,Yu Alice Chen,Beatriz N. Dardik,Frederique Chaperon,Chad Schwartzkopf,Van Nguyen-Tran,Thomas Hollenbeck,Peter McNamara,Xiaohui He,Hong Liu,H. Martin Seidel,Anneliese L. Jaton,Jesper Gromada,Sandra Teixeira +15 more
TL;DR: Together, the metabolic and CNS actions of a novel CB1 receptor inverse agonist, compound 64, and a 1,5,6-trisubstituted pyrazolopyrimidinone suggested that some separation may be achievable between central and peripheral effects with brain-penetrating CB1 receptors inverse agonists while maintaining metabolic efficacy.